Skip to Content

Generic Cyanokit Availability

Cyanokit is a brand name of hydroxocobalamin, approved by the FDA in the following formulation(s):

CYANOKIT (hydroxocobalamin - injectable;injection)

  • Manufacturer: SERB SA
    Approval date: December 15, 2006
    Strength(s): 2.5GM/VIAL (5GM/KIT)
  • Manufacturer: SERB SA
    Approval date: April 8, 2011
    Strength(s): 5GM/VIAL (5GM/KIT) [RLD]

Has a generic version of Cyanokit been approved?

No. There is currently no therapeutically equivalent version of Cyanokit available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cyanokit. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Dosage form of hydroxocobalamin and its use in cyanide poisoning
    Patent 5,834,448
    Issued: November 10, 1998
    Inventor(s): Pouchol; Gerard & Bonhomme; Yves & Poulain; Marie-Laure & Duran; Michel
    Assignee(s): Merck Patent Gesellschaft mit beschrankter Haftung
    The invention relates to a new dosage form of hydroxocobalamin which serves in the treatment of cyanide poisoning and contains hydroxocobalamin in freeze-dried form. The hydroxocobalamin is freeze-dried in an acidic medium so as to be practically instantly redissolved in a neutral saline solution. The present invention also relates to a process for producing hydroxocobalamin-based pharmaceutical compositions as well as to first aid kits containing these compositions and methods of using such kits for the treatment of cyanide poisoning.
    Patent expiration dates:
    • November 14, 2016
      Drug product
    • November 14, 2016
      Drug product
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.